John F. DiPersio

95.8k total citations · 4 hit papers
596 papers, 20.8k citations indexed

About

John F. DiPersio is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, John F. DiPersio has authored 596 papers receiving a total of 20.8k indexed citations (citations by other indexed papers that have themselves been cited), including 426 papers in Hematology, 203 papers in Oncology and 161 papers in Immunology. Recurrent topics in John F. DiPersio's work include Hematopoietic Stem Cell Transplantation (237 papers), Acute Myeloid Leukemia Research (199 papers) and Multiple Myeloma Research and Treatments (106 papers). John F. DiPersio is often cited by papers focused on Hematopoietic Stem Cell Transplantation (237 papers), Acute Myeloid Leukemia Research (199 papers) and Multiple Myeloma Research and Treatments (106 papers). John F. DiPersio collaborates with scholars based in United States, Canada and Germany. John F. DiPersio's co-authors include Michael P. Rettig, Ravi Vij, Peter Westervelt, Geoffrey L. Uy, Timothy J. Ley, Mark A. Schroeder, Julie Ritchey, Amanda F. Cashen, Richard T. Maziarz and Gary Bridger and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

John F. DiPersio

575 papers receiving 20.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Age-related mutations associated with clonal hematopoietic expansion and malignancies

2014 1.2k citations Daniel C. Link, John F. DiPersio et al. profile →
Decitabine improves patient outcomes in myelodysplastic syndromes

2006 1.1k citations Hagop M. Kantarjian, John F. DiPersio et al. profile →
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma

2009 579 citations John F. DiPersio, Auayporn Nademanee et al. Blood profile →
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

2009 512 citations John F. DiPersio, Ivana N. Micallef et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by John F. DiPersio

Since Specialization

Citations

This map shows the geographic impact of John F. DiPersio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John F. DiPersio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John F. DiPersio more than expected).

Fields of papers citing papers by John F. DiPersio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John F. DiPersio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John F. DiPersio. The network helps show where John F. DiPersio may publish in the future.

Co-authorship network of co-authors of John F. DiPersio

This figure shows the co-authorship network connecting the top 25 collaborators of John F. DiPersio. A scholar is included among the top collaborators of John F. DiPersio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John F. DiPersio. John F. DiPersio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	NKTR-255 enhances complete response following CD19 CAR T-cell therapy in patients with relapsed/refractory large B-cell lymphoma 2025 ·Blood Advances ·Sairah Ahmed, John F. DiPersio, James Essell, Catherine Diefenbach, Miguel‐Angel Perales, Cristina Castilla‐Llorente, Saurabh Dahiya, (unknown), (unknown), Christie Fanton, Sohail S. Chaudhry, Zachary Lee, (unknown), Mary Tagliaferri, Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk	1
2	NKTR-255 Vs Placebo to Enhance Complete Responses and Durability Following CD19-Directed CAR-T Therapy in Patients with Relapsed/ Refractory (R/R) Large B-Cell Lymphoma (LBCL) 2025 ·Transplantation and Cellular Therapy ·Sairah Ahmed, John F. DiPersio, James Essell, Catherine Diefenbach, Miguel‐Angel Perales, C. Llorente, Saurabh Dahiya, (unknown), Christie Fanton, Sohail S. Chaudhry, Zachary Lee, (unknown), (unknown), Jonathan Zalevsky, David B. Miklos, Cameron J. Turtle, Joseph P. McGuirk	1
3	Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL) 2024 ·Transplantation and Cellular Therapy ·Armin Ghobadi, Ibrahim Aldoss, Shannon L. Maude, Deepa Bhojwani, Alan S. Wayne, Ashish Bajel, (unknown), Rawan Faramand, Ryan J. Mattison, Michael P. Rettig, Kenneth Jacobs, Ouiam Bakkacha, John Muth, (unknown), (unknown), (unknown), (unknown), Matthew Cooper, Jan Davidson‐Moncada, John F. DiPersio	1
4	A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML) 2024 ·Blood ·John F. DiPersio, Guenther Koehne, Nirali N. Shah, Léa Bernard, Hyung C. Suh, Divya Koura, Miguel‐Angel Perales, Roni Tamari, Muhammad Umair Mushtaq, Joseph Maakaron, Michael R. Loken, (unknown), (unknown), Saurabh S. Thosar, Sharon L. Hyzy, Glen Raffel, Brenda Cooper	0
5	Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc 2023 ·Blood Advances ·Julie O’Neal, Matthew Cooper, Julie Ritchey, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Feng Gao, Byung Ha Lee, Donghoon Choi, Melissa M. Berrien-Elliott, Alice Y. Zhou, Todd A. Fehniger, (unknown), John F. DiPersio	20
6	A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation 2022 ·Transplantation and Cellular Therapy ·Ramzi Abboud, Feng Gao, Michael P. Rettig, (unknown), Leah Gehrs, Nicholas A. Wallace, Camille N. Abboud, Peter Westervelt, Geoffrey L. Uy, Amanda F. Cashen, Matthew Christopher, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith Stockerl-Goldstein, John F. DiPersio, Mark A. Schroeder	1
7	Safety analysis of patients who received ruxolitinib for steroid-refractory acute or chronic graft-versus-host disease in an expanded access program 2022 ·Bone Marrow Transplantation ·Mark A. Schroeder, Parameswaran Hari, (unknown), Dilan Paranagama, Valkal Bhatt, John F. DiPersio	7
8	Use of Belimumab for Prophylaxis of Chronic Graft-Versus-Host Disease 2021 ·Blood ·Iskra Pusic, Tanner M. Johanns, Stefanie Sarantopoulos, (unknown), (unknown), Peter Westervelt, Amanda F. Cashen, Geoffrey L. Uy, Camille N. Abboud, John F. DiPersio	1
9	VLA4-Targeted Nanoparticles Hijack Cell Adhesion–Mediated Drug Resistance to Target Refractory Myeloma Cells and Prolong Survival 2020 ·Clinical Cancer Research ·Francesca Fontana, Michael J. Scott, John S. Allen, Xiaoxia Yang, Grace Cui, Dipanjan Pan, (unknown), Mark A. Fiala, Julie O’Neal, (unknown), Julie Ritchey, Michael P. Rettig, (unknown), Steven Fletcher, Ravi Vij, John F. DiPersio, Gregory M. Lanza	19
10	Engraftment of rare, pathogenic donor hematopoietic mutations in unrelated hematopoietic stem cell transplantation 2020 ·Science Translational Medicine ·Winghing Wong, Sima Bhatt, Kathryn Trinkaus, Iskra Pusic, Kevin Elliott, Nitin Mahajan, Fei Wan, Galen E. Switzer, Dennis L. Confer, John F. DiPersio, Michael A. Pulsipher, Nirali N. Shah, Jennifer A. Sees, (unknown), Jamie R. Blundell, Bronwen E. Shaw, Todd E. Druley	36
11	A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease 2020 ·Blood Advances ·Mark A. Schroeder, H. Jean Khoury, Madan Jagasia, Haris Ali, Gary J. Schiller, Karl Staser, Jaebok Choi, Leah Gehrs, Michael Arbushites, Ying Yan, Peter Langmuir, (unknown), Michael A. Pratta, Miguel‐Angel Perales, Yi‐Bin Chen, Gabrielle Meyers, John F. DiPersio	72
12	A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory B-Cell Lymphoma 2019 ·Clinical Cancer Research ·Joseph M. Tuscano, Emanual Maverakis, Susan Groshen, Denice Tsao‐Wei, Guillaume Luxardi, Alexander A. Merleev, Anne Beaven, John F. DiPersio, Leslie Popplewell, Robert Chen, Mark Kirschbaum, Mark A. Schroeder, Edward M. Newman	34
13	Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis 2015 ·Biology of Blood and Marrow Transplantation ·Armin Rashidi, Maryam Ebadi, Graham A. Colditz, John F. DiPersio	65
14	Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation 2013 ·Blood ·Christopher Bredeson, Jennifer Le‐Rademacher, Kazunobu Kato, John F. DiPersio, Edward Agura, Steven M. Devine, Frederick R. Appelbaum, Marcie Tomblyn, Ginna G. Laport, Xiaochun Zhu, Philip L. McCarthy, Vincent T. Ho, Kenneth R. Cooke, (unknown), (unknown), J. Douglas Rizzo, (unknown), Marcelo C. Pasquini	88
15	A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia 2012 ·Blood ·Geoffrey L. Uy, Michael P. Rettig, Ibraheem Motabi, Kyle McFarland, Kathryn Trinkaus, Lindsay Hladnik, Shashikant Kulkarni, Camille N. Abboud, Amanda F. Cashen, Keith Stockerl‐Goldstein, Ravi Vij, Peter Westervelt, John F. DiPersio	310
16	A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia 2010 ·Blood ·Todd A. Fehniger, Geoffrey L. Uy, Kathryn Trinkaus, (unknown), (unknown), Camille N. Abboud, Amanda F. Cashen, Keith Stockerl‐Goldstein, Peter Westervelt, John F. DiPersio, Ravi Vij	82
17	Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome 2010 ·Journal of Clinical Oncology ·Brian McClune, Daniel J. Weisdorf, Tanya L. Pedersen, Gisela Tunes da Silva, Martin S. Tallman, Jorge Sierra, John F. DiPersio, Armand Keating, Robert Peter Gale, Biju George, Vikas Gupta, Theresa Hahn, Luis Isola, Madan Jagasia, Hillard M. Lazarus, David I. Marks, Richard T. Maziarz, Edmund K. Waller, Christopher Bredeson, Sergio Giralt	338
18	Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma breakdown → 2009 ·Journal of Clinical Oncology ·John F. DiPersio, Ivana N. Micallef, Patrick J. Stiff, Brian J. Bolwell, Richard T. Maziarz, Eric D. Jacobsen, Auayporn Nademanee, John M. McCarty, Gary Bridger, Gary Calandra	512
19	Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up 2009 ·Blood ·Hagop M. Kantarjian, Jörge E. Cortes, Dong‐Wook Kim, Pedro Enrique Dorlhiac‐Llacer, Ricardo Pasqüini, John F. DiPersio, Martin Müller, Jerald P. Radich, H. Jean Khoury, Н Д Хорошко, M. Brigid Bradley‐Garelik, Chao Zhu, Martin S. Tallman	127
20	Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction 2008 ·Blood ·Steven M. Devine, Ravi Vij, Michael P. Rettig, Laura Todt, (unknown), Nicholas M. Fisher, Hollie Devine, Daniel C. Link, Gary Calandra, Gary Bridger, Peter Westervelt, John F. DiPersio	234

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact